Total medical devices industry M&A deals worth $7.4bn were announced in the US in April 2021, with $5bn merger of CA Healthcare Acquisition and LumiraDx being the sector’s biggest investment, according to GlobalData’s deals database.
- Embed this chart
Embed this chart into your website
Copy and paste the image source into your website to display the chart.
The value marked an increase of 232.3% over the previous month of $2.23bn and a rise of 2.1% when compared with the last 12-month average of $7.26bn.
The US held an 80.81% share of the global medical devices industry M&A deal value that totalled $9.17bn in April 2021.
In terms of M&A deal activity, the US recorded 23 deals during April 2021, marking a flat growth over the previous month and a flat growth over the 12-month average.
US medical devices industry M&A deals in April 2021: Top deals
The top five medical devices industry M&A deals accounted for 98.4% of the overall value during April 2021.
The combined value of the top five medical devices M&A deals stood at $7.29bn, against the overall value of $7.4bn recorded for the month.
The top five medical devices industry M&A deals of April 2021 tracked by GlobalData were:
1) The $5bn merger of CA Healthcare Acquisition and LumiraDx
2) The $1.8bn acquisition of Luminex by DiaSorin
3) InVitae’ $200m acquisition of Genosity
4) The $187m acquisition of Better Therapeutics by Mountain Crest AcquisitionII
5) The merger of D8 and Vicarious Surgical for $102.15m.
Verdict deals analysis methodology
This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.
GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.
More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.